Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850574 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study of Chronic Myelomonocytic Leukemia and Leukemia, Myeloid, Acute, sponsored by Aptose Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT03850574: Recruiting Phase 1 study of Chronic Myelomonocytic Leukemia and Leukemia, Myeloid, Acute, sponsored by Aptose Biosciences.
NCT03850574 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Leukemia, Myeloid, Acute that is actively recruiting participants, run by Aptose Biosciences. The registered enrollment target is 240 participants, above the 85-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03850574, a Phase 1 study of Chronic Myelomonocytic Leukemia and Leukemia, Myeloid, Acute, is actively recruiting participants, sponsored by Aptose Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
Conditions Studied
Interventions
- DRUG Tuspetinib
- DRUG Venetoclax Oral Tablet
- DRUG Azacitidine for Intravenous Infusion
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Irvine - Irvine
- UCSD Moores Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Stanford Cancer Center - Palo Alto
- University of California, Davis - Sacramento
Ohio
- Cleveland Clinic - Taussig Cancer Center - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Queensland
- Royal Brisbane and Women's Hospital - Herston
- Townsville University Hospital - Townsville
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
Connecticut
- Yale University - New Haven
Florida
- University of Miami - Miller School of Medicine - Miami
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT03850574 shows while recruiting
NCT03850574 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (182% higher).
The record links to 5 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Tuspetinib is the first listed.
NCT03850574 names 20 study sites across 13 states, led by California, Ohio, Queensland.
Frequently Asked Questions
What is clinical trial NCT03850574 about?
NCT03850574 is a clinical study titled "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia". The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMM...
What is the current status of trial NCT03850574?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2019-03-11. Estimated completion is 2027-04.
What conditions does trial NCT03850574 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndrome With Excess Blasts-2, Refractory AML, Relapsed Adult AML.
What interventions are being tested in trial NCT03850574?
The interventions under investigation include: Tuspetinib (DRUG), Venetoclax Oral Tablet (DRUG), Azacitidine for Intravenous Infusion (DRUG).
Who is sponsoring clinical trial NCT03850574?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850574 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03850574's enrollment target sits among peer trials
240 7th of 73 higher than 67 of 73 other Chronic Myelomonocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelomonocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
-
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI